Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminates Alloreactive Host Immune Cells in SLE Donor PBMCs SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.

现成的，靶向CD19的CAR NK细胞产品候选物驱动SLE供体CD19+B细胞的快速和深度消耗ADR技术结合到FT522中诱导功能持久性并消除SLE供体PBMC中的同种异体反应性宿主免疫细胞。圣地亚哥，2024年5月3日（环球通讯社）-命运治疗公司。

(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

（NASDAQ:FATE）是一家临床阶段的生物制药公司，致力于为癌症和自身免疫性疾病患者提供一流的诱导多能干细胞（iPSC）衍生细胞免疫疗法，今天宣布，一份最新的摘要将于2024年5月7日至11日在马里兰州巴尔的摩举行的美国基因与细胞治疗学会（ASGCT）第27届年会上展出其FT522自身免疫性疾病项目的临床前数据。

FT522 is the Company’s CD19-targeted, iPSC-derived CAR NK cell product candidate that incorporates its novel alloimmune defense receptor (ADR) technology, which is designed to increase the potency of off-the-shelf cell therapy and enable treatment without administration of conditioning chemotherapy to patients.

FT522是该公司靶向CD19的iPSC衍生的CAR NK细胞候选产品，它结合了其新型同种免疫防御受体（ADR）技术，旨在提高现成细胞疗法的效力，并使治疗无需对患者进行调理化疗。

At the ASGCT conference, the Company will present multiple preclinical studies displaying the function of FT522 using peripheral blood mononuclear cells (PBMCs) sourced from unmatched donors with systemic lupus erythematosus (SLE). These preclinical data demonstrate rapid and deep B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells, indicating that FT522 may deliver therapeutic benefit to patients with autoimmune diseases without requiring administration of conditioning chemotherapy.

在ASGCT会议上，该公司将展示多项临床前研究，显示FT522的功能，这些研究使用的是来自无与伦比的系统性红斑狼疮（SLE）供体的外周血单核细胞（PBMC）。这些临床前数据表明，B细胞耗竭迅速而深入，功能持久性增强，并消除了同种异体反应性宿主免疫细胞，这表明FT522可以为自身免疫性疾病患者提供治疗益处，而无需进行调理化疗。

Late-breaking abstracts are available on the ASGCT Annual Meeting website. Presentation details are as follows: PresentationFT522.

ASGCT年会网站上提供了最新的摘要。演示详细信息如下：PresentationFT522。